Literature DB >> 19236272

Under the radar: balamuthia amebic encephalitis.

Frederick L Schuster1, Shigeo Yagi, Shilpa Gavali, David Michelson, Ravi Raghavan, Ingrid Blomquist, Christine Glastonbury, Andrew W Bollen, David Scharnhorst, Sharon L Reed, Steve Kuriyama, Govinda S Visvesvara, Carol A Glaser.   

Abstract

BACKGROUND: We present data from 9 years (1999-2008) of tests for Balamuthia mandrillaris, an agent of amebic encephalitis that were conducted as part of the California Encephalitis Project.
METHODS: Specimens obtained from patients with encephalitis were sent to the California Encephalitis Project for diagnostic testing; a subset of these specimens were tested for Balamuthia species. Tests included indirect immunofluorescent staining of sections for amebae, fluorescent antibody staining and enzyme-linked immunosorbent assay for serum titers, and polymerase chain reaction for Balamuthia 16S mitochondrial DNA. Cerebrospinal fluid (CSF) samples obtained from patients with diverse types of encephalitis were also tested for a broad range of cytokines.
RESULTS: Of >3500 cases referred to the California Encephalitis Project, 10 were found to be amebic encephalitis on the basis of serologic and CSF tests and examination of stained tissue sections. Most of these cases would have been described as "encephalitis of unknown origin" if it were not for the California Encephalitis Project. Nine of the 10 patients were male; ages ranged from 1.5 to 72 years. All patients had abnormal neuroimaging findings and abnormal CSF composition. The more common symptoms at presentation included headache, seizures, cranial nerve palsies, and lethargy. CSF specimens from patients with Balamuthia infection had significant elevations in the levels of cytokines IL-6 and IL-8, compared with specimens obtained from persons with viral or noninfectious encephalitides.
CONCLUSIONS: Balamuthiasis is difficult to diagnose, and it is likely that cases go unrecognized because clinicians and laboratorians are unfamiliar with the disease. Alerting the medical community to this disease may lead to earlier diagnosis and improve the chances of survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236272     DOI: 10.1086/597260

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Balamuthia mandrillaris amoebic encephalitis: an emerging parasitic infection.

Authors:  Francisco G Bravo; Carlos Seas
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Serologic survey for exposure following fatal Balamuthia mandrillaris infection.

Authors:  Brendan R Jackson; Zuzana Kucerova; Sharon L Roy; Glenda Aguirre; Joli Weiss; Rama Sriram; Jonathan Yoder; Rebecca Foelber; Steven Baty; Gordana Derado; Susan L Stramer; Valerie Winkelman; Govinda S Visvesvara
Journal:  Parasitol Res       Date:  2014-01-24       Impact factor: 2.289

3.  Emerging and reemerging neurologic infections.

Authors:  Felicia C Chow; Carol A Glaser
Journal:  Neurohospitalist       Date:  2014-10

4.  Transmission of Balamuthia mandrillaris through solid organ transplantation: utility of organ recipient serology to guide clinical management.

Authors:  A A Gupte; S N Hocevar; A S Lea; R D Kulkarni; D C Schain; M J Casey; I R Zendejas-Ruiz; W K Chung; C Mbaeyi; S L Roy; G S Visvesvara; A J da Silva; J Tallaj; D Eckhoff; J W Baddley
Journal:  Am J Transplant       Date:  2014-05-19       Impact factor: 8.086

5.  Identification of antigenic targets for immunodetection of Balamuthia mandrillaris infection.

Authors:  Zuzana Kucerova; Rama Sriram; Patricia P Wilkins; Govinda S Visvesvara
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

Review 6.  Encephalitis in US Children.

Authors:  Kevin Messacar; Marc Fischer; Samuel R Dominguez; Kenneth L Tyler; Mark J Abzug
Journal:  Infect Dis Clin North Am       Date:  2017-12-08       Impact factor: 5.982

7.  The isolation of Balamuthia mandrillaris from environmental sources from Peru.

Authors:  Alfonso Martín Cabello-Vílchez; María Reyes-Batlle; Esmelda Montalbán-Sandoval; Carmen Ma Martín-Navarro; Atteneri López-Arencibia; Rafaela Elias-Letts; Humberto Guerra; Eduardo Gotuzzo; Enrique Martínez-Carretero; José E Piñero; Sutherland K Maciver; Basilio Valladares; Jacob Lorenzo-Morales
Journal:  Parasitol Res       Date:  2014-04-30       Impact factor: 2.289

Review 8.  Antiparasitic therapy.

Authors:  Shanthi Kappagoda; Upinder Singh; Brian G Blackburn
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

9.  Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain.

Authors:  Sharon L Roy; Jane T Atkins; Rosemaria Gennuso; Danny Kofos; Rama R Sriram; Thomas P C Dorlo; Teresa Hayes; Yvonne Qvarnstrom; Zuzana Kucerova; B Joseph Guglielmo; Govinda S Visvesvara
Journal:  Parasitol Res       Date:  2015-09-02       Impact factor: 2.289

10.  Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Authors:  A Venkatesan; A R Tunkel; K C Bloch; A S Lauring; J Sejvar; A Bitnun; J-P Stahl; A Mailles; M Drebot; C E Rupprecht; J Yoder; J R Cope; M R Wilson; R J Whitley; J Sullivan; J Granerod; C Jones; K Eastwood; K N Ward; D N Durrheim; M V Solbrig; L Guo-Dong; C A Glaser
Journal:  Clin Infect Dis       Date:  2013-07-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.